Tesla Vision Corporation (TSLV)

[wafflestomper]

press release

http://biz.yahoo.com/pz/070618/121514.html

Source: Advanced Medical Isotopes Corporation

Advanced Medical Isotopes Corporation Completes Purchase of the Life Sciences Division From Isonics Corporation
Monday June 18, 8:57 am ET

KENNEWICK, Wash., June 18, 2007 (PRIME NEWSWIRE) -- Advanced Medical Isotopes Corporation (AMIC) (Other OTC:ADMD.PK - News) becomes an immediate isotope provider of stable and radioactive isotopes while engaging in the development of advanced production systems and processes for bringing previously unavailable medical isotopes to the marketplace, has completed the purchase of the Life Sciences division of Isonics for $850,000. The Life Sciences division of Isonics (see http://www.isonics.com) has had profitable sales of over $5,000,000 over the past two fiscal years.

With the Life Sciences purchase, AMIC gains a re-seller arrangement and extensive business acumen, along with scientific relationships via the USIC- IPP program with two major suppliers of isotopes in Russia, as well as a commercial arrangement with Central Radiopharmaceutical Services, utilizing the 30 MEV cyclotron at the State University of New York at Buffalo. AMIC now immediately gains production capability and instant commercial entry into the emerging markets of Indium-111, Actinium-225, Oxygen-18, as well as the four major PET isotopes, and importantly, current customers varying from radiopharmacies, to Universities and leading Research Centers, as well as several leading hospitals across the nation.

``We understand the extraordinary growth of U.S. demand for medical imaging products will reach $21.4 billion by 2010, and AMIC is positioning itself to take full advantage of that growth. Nuclear medicine, for both diagnosis and therapeutic purposes is growing at double-digit rates. Furthermore, both China and India are experiencing tremendous growth curves utilizing medical isotopes, and we are exploring strategic relationships with other companies involved in those geographic areas,'' stated William J. Stokes, CEO.

AMIC anticipates expanding the sales of major diagnostic Indium-111, therapeutic medical isotopes Actinium/Bismuth -213 as well as Oxygen-18 (used in PET) and further rapid expansion into the production of other high margin medical isotopes, by fully deploying the marketing personnel of the Life Sciences unit in conjunction with the tutelage from the Chief Science Officer. Isotopes produced by AMIC uniquely positions the company to utilize its first linear accelerator machine in Kennewick, Washington (as well as using the 30 MEV cyclotron in New York) to license and joint venture with Universities, Research Centers and hospitals, and the United States National Laboratories, as well as commercial arrangements with radiopharmaceutical companies for the treatment and diagnosis of diseases.

Chief Science Officer Dr. Robert Schenter said, ``The dozens of isotopes that AMIC expects to produce will assist new areas of research and treatment that have not been achievable without our cost-effective proprietary technology.''

About AMIC

Advanced Medical Isotopes Corporation is engaged in the development of advanced production systems and processes for bringing previously unavailable medical isotopes to the marketplace and advancing systems for local product production. The field of nuclear medicine has routinely utilized radioisotopes in the diagnosis of disease while new processes are being pioneered for the targeted treatment of diseases such as cancer in preference to surgical techniques. Advanced Medical Isotopes Corporation products support the accessibility to these less invasive therapeutic processes by advancing systems for lower cost production and improving supply availability of medical isotopes to hospitals and clinical treatment centers. For more information, please visit http://www.advancedmedicalisotopes.com.

Forward-Looking Statements

Except for historical information contained herein, the matters set forth in this press release, such as statements relating to the company's ability to drive technological developments and the acceptance and timing of product introductions, are forward-looking statements that are subject to risks and uncertainties, including but not limited to, timely development and acceptance of new products, the impact of competitive products and pricing, the timely development and release of products by suppliers, and other risks.

Contact:Advanced Medical Isotopes Corporation
James C. Katzaroff
[phone]
Fax: [phone]

--------------------------------------------------------------------------------
Source: Advanced Medical Isotopes Corporation